Cargando…

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation

We evaluated high-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. One hundred and seventy-four consecutive patients who were at risk for CMV infection (either recipient or donor seropositive) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, R, Cortez, K, Solomon, S, Battiwalla, M, Gill, VJ, Hensel, N, Childs, R, Barrett, AJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2002
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091676/ https://www.ncbi.nlm.nih.gov/pubmed/12203140 http://dx.doi.org/10.1038/sj.bmt.1703648

Ejemplares similares

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
por: Zhu, Shengyun, et al.
Publicado: (2021)

Correction: The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
Publicado: (2022)

Second Hematopoietic Stem Cell Transplantation for Leukemia Relapsing after Myeloablative T Cell Depleted Transplants Does Not Prolong Survival
por: McIver, Zachariah A., et al.
Publicado: (2013)

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction
por: van Balen, Peter, et al.
Publicado: (2018)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
por: Campbell, P, et al.
Publicado: (2014)

Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis
por: Kim, Dong Hyun, et al.
Publicado: (2022)

Comparison of Non-myeloablative Conditioning Regimens for Lymphoproliferative Disorders
por: Hong, Sanghee, et al.
Publicado: (2014)

SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
por: Luger, Selina M., et al.
Publicado: (2011)

Appropriate pre-transplant strategy for patients with myelodysplastic syndromes receiving allogeneic haematopoietic stem cell transplantation after myeloablative conditioning
por: Wang, Hong, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin
por: Park, Bo-Kyoung, et al.
Publicado: (2018)

Correction of T-Cell Repertoire and Autoimmune Diabetes in NOD Mice by Non-myeloablative T-Cell Depleted Allogeneic HSCT
por: Sidlik Muskatel, Rakefet, et al.
Publicado: (2023)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
por: Servais, Sophie, et al.
Publicado: (2015)

The Risk of Cytomegalovirus Infection in Non-myeloablative Peripheral Stem Cell Transplantation Compared with Conventional Bone Marrow Transplantation
por: Oh, Suk Joong, et al.
Publicado: (2004)

Myeloablative treatment supported by autologous stem cell infusion with neuroblastoma.
por: Ryu, Kyung Ha, et al.
Publicado: (2003)

Targeting Myeloid Cells to the Brain Using Non-Myeloablative Conditioning
por: Böttcher, Chotima, et al.
Publicado: (2013)

Splenocytes Seed Bone Marrow of Myeloablated Mice: Implication for Atherosclerosis
por: Wang, Lai, et al.
Publicado: (2015)

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
por: Wagner, John E., et al.
Publicado: (2021)

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
por: Solomon, Scott R., et al.
Publicado: (2016)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

Deep Vein Thrombosis Following Non-myeloablative Allogeneic Stem Cell Transplantation: Presentation of Three Cases and Literature Review
por: Özdemir, Evren, et al.
Publicado: (2013)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

Correction: Splenocytes Seed Bone Marrow of Myeloablated Mice: Implication for Atherosclerosis
Publicado: (2015)

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation
por: Treister, Nathaniel, et al.
Publicado: (2017)

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity
por: Stephens, Sarah J., et al.
Publicado: (2016)

Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients
por: Körholz, Katharina F., et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein–Barr virus infection
por: Luo, Yanhui, et al.
Publicado: (2022)

Successful Treatment with Ganciclovir for Cytomegalovirus Duodenitis following Allogenic Bone Marrow Transplantation
por: Ahn, Jin Hee, et al.
Publicado: (1999)

Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study
por: Sun, Zimin, et al.
Publicado: (2018)

NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir
por: Nishii, Rina, et al.
Publicado: (2021)

Pilot experience with opebacan/rBPI (21) in myeloablative hematopoietic cell transplantation
por: Guinan, Eva, et al.
Publicado: (2015)

Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation
por: Tjwa, Marc, et al.
Publicado: (2009)

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas
por: Zhenyang, Gu, et al.
Publicado: (2021)

Thrombopoietin from hepatocytes promotes hematopoietic stem cell regeneration after myeloablation
por: Gao, Longfei, et al.
Publicado: (2021)

Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome
por: Chung, Yang Jo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uo5k7n5b193gtiamhcsrsnvs6f